Dr. Ali is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Leukemia
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058
Education & Training
City of Hope National Medical CenterFellowship, Hematopoietic Cell Transplantation, 2012 - 2013
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 2004 - 2006
MedStar Health/Harbor HospitalInternship, Internal Medicine, 2003 - 2004
Rawalpindi Medical CollegeClass of 2001
Certifications & Licensure
TX State Medical License 2009 - 2026
CA State Medical License 2005 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis Start of enrollment: 2016 Nov 13
- Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Start of enrollment: 2020 Nov 11
Publications & Presentations
PubMed
- Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid ...Amanda Blackmon, Michelle Afkhami, Dongyun Yang, Sally Mokhtari, Yazeed Samara
Bone Marrow Transplantation. 2024-12-18 - Pacritinib and concurrent azole antifungal therapy is deliverable in patients with hematologic malignancies.Dina Trang, Dat Ngo, Haris Ali, Jose Tinajero
Journal of Oncology Pharmacy Practice. 2024-12-01 - Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD).Hoda Pourhassan, Tina Nguyen, Dongyun Yang, Salman Otoukesh, Shukaib Arslan
Cancers. 2024-11-22
Abstracts/Posters
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
City of Hope Doctors and Scientists Present Research on Novel Cancer Therapies at American Society of Hematology (ASH) Annual ConferenceDecember 10th, 2024
City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023- Adding Itacitinib to Conventional GVHD ProphylaxisDecember 9th, 2022
- Join now to see all
Professional Memberships
- Member
- American Society for Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
